Trial Profile
A randomized study investigating the effect of ranibizumab in patients with exudative age-related macular degeneration and vascularized pigment epithelial detachments (PED)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Dec 2015
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration; Eye disorders; Retinal detachment
- Focus Adverse reactions
- 05 Dec 2015 New trial record